Ecopia BioSciences Inc. Receives No Objection Letter From Health Canada For Cancer Phase I Clinical Trial

MONTREAL--(BUSINESS WIRE)--Feb. 2, 2006--Ecopia BioSciences (TSX:EIA) announced today that it has received a No Objection Letter from the Therapeutics Products Directorate of Health Canada for the commencement of a Phase I clinical trial relating to the Company's anticancer agent, ECO-4601.

Back to news